THROMBOSIS UK (A Company Limited by Guarantee) REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2025 Regtstered Charity No: 1090540 Company No: 4354472 L3174-2fj
THROMBOSIS UK Registered Charity No: 1090540 Company No: 4354472 TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDFD 31 JANUARY 2025 REFERENCEAND ADMINISTRATION DETAILS: TRUSTEE AND MANAGEMENT Andrea Louise Croft Dr Matthew Robert Fay Professor lan Maxwell Franklin (Resigned as Chair on 22.10.2024) Simon Hart Professor Beverley Jane Hunt OBE (Appointed as Co-chair on 22.10.2024) Stephane Jaglin Professor Sirnon Noble (Retired 04.09.2025) Robin Offord Janet Morgan (Appointed as Co-chair on 22.10.2024) Nusaiba Masnurah CEO Jo Jerrome (Resigned effective from 31.08.2025) Tiffany Richards. Inierim CEO (Appointed on 05.08.2025) Secretary Professor Beverley Jane Hunt OBE REGISTERED OFFICE Couch Bright King & Co 2 Tolherst Court Turkey Mill Business Park Ashford Road Maidstone Kent ME14 5SF AUDTfoRS Couch Bright King & Co Chartered Accountants 2 Tolherst Court Turkey Mill Business Park Ashford Road, Maidstone Kent ME14 5SF SOLicfTORS Stone King 28 Ely Place London ECIN 6TD BANKERS National Westininster Bank PLC Malda Vale Elgin Avenue 127 Kilburn Road London NW6 6JL
THROMBOSIS UK Registered Charity No: 1091)540 Company No: 4354472 TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025 The Trustees present their annual report and the financial statements for the year ended 31 January 2025. The fanCIal statements have been prepared in accordance with the accounting policies set out on pages 18 to 19, and comply with the Charities Act 2011, thL Stalement of Recommended Practice (SORP) applicable to chltieS prcparing their accounts in accordance with ihe Financial Reporting Standard applicable ID the UK Republic of treland (FRS 102), published in October 2019 and the CoTnpanics Act 2006. Thrombosis UK is a charitable company limiicd by guarantee. incorporated on 16 January 2002 and registered as a charity on 12 February 2002. It has no share capital. Accordingly. the report and fmancial statemenls also comply with the requirements of the Companies Aci 2006. Opening statement from Thrombosis UK co-chairs For many years. we have been exceptionally fortunate to have stability at Thrombosis UK in tern]s of a dedicated team and boJrd of trustees. This year that changed. Our chair, lan Franklin. who successfully led the charity for nine years. including the challenges of the pandemic. chose to step down. and our long-serviT]g patient support and helpline lead AnT]ya, left to pursue other interests. Both individuals have made a lasting contribution to the organisation. lan's calm and considered leadership has beeD iTnmense. Over her 17 years. Annya has supported countless patients and family members better understand and adapt to life after VTB. Throughout this time, the other employees and supporters of the charity continued to exceed expectations and ensure Thrombosis UK provides a breadth of support to our community. Thanks to that team, it bas been a successful and busy y. The Charity has delivered a wide range of valuable and qlllty educational and patient support activities. We have continued our efforts to Taise awareness of thrombosis and expanded our digital channels as a way to reach more people. We have also taken steps to enhance our governance and securiry and continue to support and undertake research. With the changes within the charity and externally, it was with some trepidation that the iwo of us took on the responsibility of co-chairs. We are commiiied io coniinuing the work lan began before the pandemic- reviewing our long-tern] strategy outlining how we best can save lives and prevent suffering caused by blood clots. As we ]k to the year ahead, there is rnuch to be proud of - and much still to do. Strengthening the chIty's long-lerni sustainability will be a key focus. including exploring new ways to diversify and grow our income so that we can expand our reach and irnpact evcn funber. We would like io close with thank5. A heartfelt thanks to our fellow trustees and uur employees. who have led the charity with resilience And purpose. And to our supporters and volunteers - those individuals who tAke on anwing challenges and give so generously of Iheir time. Without you. Thrombosis UK would not be her¢. Thank you to each Rnd every one of you. J Morgan & B Hunt Co-chairs. Throtnbosis UK
THROMBOSIS UK Registered Charlty No: 1090540 Company No: 4354472 TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025 OBJECTIVES AND STRATEGIES Thrombosis UK was established to advance medical science in relalion to tILe dÈagnosis, cause5, Prevention, alleviation. managemenL and cure of thrombosis and for the Promotion of l(nowledge and public education of the understanding and aWelless of thrombosis. Using the powers confetred by the Memorandum of Association, Thrombosis UK ain]s to fund: A range of studies looking ai why and how a thrombosis occurs. Rearch into the management and the improvement of current treaLTnents available. An education prOgrarnn that infonns people about the causes, effects, prevention, and recommended management of thrombosis. Provide a network of support for those affected by thrombosis. ORGANISATION AND STRUCTURE The Board of Trustees, who are also Directors OF the company, govern Thrombosis UK. The Trustees have the power to appoint, and remove any member. any member to act as Secretary to the Charity and all vote on the appointment of the Chair. Treasurer. and other Honorary Officers. The charity seeks to ensure Trnstees are appointed to fulfil the changing and on-going needs of the charity's activilies and outcomes. A Trustee job description is agreed when vacancies become available to ensure existing and new Twstees have ClAtY on their roles and they each bring skills that complement and benefit Thrombosis UK. New Trusiees are appointed with the unanimous approval of existing Trusiees, All Trustees give freely of their time and expertise and receive no remuneration for their worL The day-to-day administration of the Charity is the responsibility of the Chief Executive Officer employed on a 0.8 pernlanenl FTE contraci. The current CEO resigned with effect from 31 August 2025, and an Interim CEO has been appointed with effect from 5 August 2025. The Patient Support and Helpline Lead Tole is employed on a 0.8 pennanent contract. This role has been vacanf since 12 DeTber 2024 pending review. The Tole of Admin and Fundraising Administrator on a 0.6 permanent contract, was increased to 0.8 fn)m I Septeber 2024, for the Ye under review. The role became vacant effective from 4 July 2025. In 2022 the Charity appointed a Clinical Psychologist on a 0.5 two-year FfE contract starting l February 2022. Following review, tbis was extended in January 2024 for a further two years until 31 January 2026. In Septernber 2024. the Trnstees appointrd a temporary 0.4 Consultant as Operations Lead until 31 May 2025. AIMS AND ACTIVITIES The Charity aims to promote greater awareness and understanding of venous thromboembolism (VIE) to improve: Prevention of avoidable blo(Kl clots. Timely detection and prompt diagnosis of VTE. Appropriate management that improves patient outcomes. Timely support and education to enable patients to restore their well-being and health. To support achievement of this, the Charity concentrates on three key areas. Awareness Education Research
THROMBOSIS UK Registered Charity No.. 1090540 Company No: 4354472 TRUSTEKS, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025 AWARENESS Raising awareness remains a key obje¢five of the charily's work. encompassing both specific awareness activities and creating oppothnities through linked initiatives. During 2024. the charity exlended its reach and awareness through rnultiple activities. including= - Exhibiting in Wales at several Aderidd's 'Lel's Get Physical, campaign in Carniarthen and Wrexham. - Having a table exhibition at the Royal Welsh Show. Presenting in-person and within online Tneetings lo trainee tlledical studcnis, nursing networks and industrylwork settings. Online. the charity reviewed its social media platfonns. expanding to include Blue Sky and streamlining its LinkedIn presence via a business page. Next step5 will be to expand training. focusing on design and AI, to promote engagement. Working in collaboratio7) with like-minded European patient groups to develop an awareness-raising social media campaign - 'Think Thrombosis, is due to launch in early 2025 and will consolidate key messages around awareness, knowledge and recognition of the common risks. signs and symptoms for blood clots. In July 2024. the new Thrombosis UK website was launched. Developed following liaison and focus group meetings with stakeholders who regulaTly use the website, the new plaiforni is much more user-friendly, easier to navigate. and provides illcreased opportunities for the charity, including an e-commerce shop. an accredited educational platform area, and can be IgelY managed by staff. FeedbaLk in the rst few months has been extren]ely EKlSitive from patient and HCP users. Popular patient infonnation resources have been Tefrcshed with new designs but all in keeping with the Thrombosis UK brand and fresh new website, while those needing to be updatcd were completed during 2024 as well a8 new titles added - including CeiebraL Venous Sinus Thrombosis (CVST), vfE in children and adolescents and. Thrombosis Prevention in Lower Limb Immobilisation. In the first quarier after launch, the sit¢ had welcomed just over 10,IKJO visits. Monitoring site data, the team are pleased to see 'Organic Sear¢h' &s one of the top ways the website is found. reflecting search engine results are 'finding' us! Direct. organic Sla1 and refeLTal are the next most common.
THROMBOSIS UK Registered Charity No: 1090540 Company No: 4354472 TRUSTEKS, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025 Education The charity is comnLiiied to advancing education and understanding of venous thromboembolism (VTE) among patients, healthcare providers, and the publi¢. In 2024, we continued to host the highly regarded 'National Thrombosis Week. (NTW'24) and 'Let's Tallc Clots. (LTC'24) virtual conferences, while <ilongside these. we established regular online patient meetings and focused events. Both virtual conferences received continuing Professional development credits (CPD) from the Royal College of Pathologists. Nfw'24 featured 21 sessions, welcomed 54 faculty rnernbe. secured 17 CPD credils. and attracted 2,733 rcgistrations from healthLare professionals. While primarily UK-based, our atteT]dee% rcpresented 54 different countries! The conterence incorporated webinars. small group 'round table. discussions. and an array ol wster exhibitions and oral PTesentalions. Feedback listed agcnda topics. ease of access to live aT]d catch-up recordings aT]d CPD accredilation as the top three reason8 delegates chose to registcr. LTC'24 set a new reLord with 2.985 registrations from healthcare and allied pri)fessionaIs across 59 countries. demonslrating our global impact. Live Webin attendance ranged from 131 to 520, and follow-up recordings consistently drew over 940 view5. Notably, we experienced increased interaction during the live week. with participants actively engaging in quesiions and discussions. Despite facing unexpected challenges within the organisation from mid-2024, we successfully hosted 11 Patient Informatlon sessions and regular 'Coffee and Chat, meettngs. We were fortunate to have the support of leading specialists in VTE. including Prof Paul Bennett, Andrea Croft. Dr. Susie Shapiro. and Dr. Will Lester, alongside patient representatives, including ex-patient Trustee and patient advocate, Shaun Kinghorn. Our Let's Talk Clots app has proven to be an invaluable educational resouT¢e. achieving 5,900 downloads and maintaining a remarkable 92% activity rate after download. The number of hospiLqls and medical settings promoting the app has surged, with rising requests for app posters and cards from primary care providers. In August 2024, NHS Scotland endorsed eight Thrombosis UK patient resources, including app promotion postcards, with the NHS Healthier Scotlalld logo. This endorsemeni allows all Scottish medical settings to utibse these resources seamlessly, without needing local reviews. This achievernent has been enthusiastically welcomed by both the Thrombosis UK t&qm and Scottish VTE healthcare professiollals.
THROMBOSIS UK Registered Charity No: 1090540 Company No: 4354472 TRUSTEE&i' ANNUAL REPORT FOR THE YEAR FNDED 31 JANUARY 2025 RESEARCH Phase One of the 'Dete£t VTE, project, aimed at overcoming barriers to the diagnosis of VTE, kicked off at the start of 2024. A total of 49 GP practices from across mainland UK volunteered to porticipate. collectively providing care for over 400,(K)O people. The initial audit w&s completed by June 2024, leading to an in-depth analysis of the data. We are gratethl to have secured pro bono support from Costello Medical to assist us in tbis important work. Detect VTE audit was the first of its kind, looking at the journey of individuals diagnosed with a VTE in the previous 12 months and their journey in the eight weeks prior to confirn)ed diagnusis. IAX)king at presentatioll symploms, risk faLlors. ld the number of presentations in the eight weeks before diagnosis was madc. as well as where individuals presented duriDg this journey. A paper detailing this work is due to be published in mid-2025. Thc woik could not have been accomplished without voluntary involvemeT]t frotn the primary practices and Thrombosis UK'S Trustee and GP Lead. Dr Matthew Fay. This involvement should be both acknowledged and sinccrcly thanked. Following the audit. each practice received a detailed report of their praclic¢'s audit. was given the opportunity to have a l-l discussion session with th¢ Medical Lead (Dr Matthew Fay) and an in-house educalional session for all practice members. Approximately three-quarters requested the l- I feedback discussion. and around one- third. an educational event. The work with Detect ITE now moves to Phase Two. and the development of an rr clinical tool to provnpt investigation should suspicion of vfE be indicated. Early work on a ¢Stocklngs Otr campaign, working in collaboration with the British Society for Haematology (BSH) has been initiated, with a freedom of inforn)ation request (FOI) to NHS Procurement seeking to secure dala on the number of compression stocking purchased by NHS England over a 12-month period (O1108123-311074). Although not possible to have exact figures due to procurement pathways and variation in Coding, we &sked NHS Supply Chain (80 IYo+ QTdered via them), who confmed more than 2.726,723. burther work on the Stockings Off campaign is expected io siart mid-2025. The charity's involvement in research sdIeS has increased with regulaT Tequests to secure 'Patient and Public Involvenient, (PPI). Patient supporters have been very interested in being involved. and the chaTity h&8 hosted a range of online meeting5. including: What Is PPI?_ intended for a patient audicnce. What PPI involvement should and shOld not include- intended for a healthcare professional audience. Individual collaboration with UK-TReN, HacmSTAR and Oxford University Hospilals on focused topics seeking PPI involvement and discussion on research design and priority areas for vfE-related research. As interest and support have grown, Thrombosis UK'S Professional Advisory Committee (PAC) worked to develop a 'Research Policy, for the charity, so that reSnSe to requests can always be balanced and reflect the values and focus of the ¢harity.
THROMBOSIS UK Registered Charity No: 1090540 Company No: 4354472 TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025 REGAIN Thrombosis UK'S RFGAIN project initially intended to provide free. online access to clinical psychological support for individuals didgnosed with Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT). but who were unable 10 access local psychological support. Since 2023. the L"mphasis of tbe REGAIN service has been to provide a general support service to people who have experienced a non-VITT-related thrombosis. The service has had three key foci: Providing one-t(Fonc or group support. directly working with people who have expeTienccd some for of vrE. 2. Further developing ihe infornmtion PTovisiun accessible on the new wcbsifr for people eXrienCillg psychological dislress followin¥ VTE and extending the focus lo wider behavioural change. Development of a trnIng package for health professionals related to communication skillq. inilially available via the new website in a non-interaLtive fornt, and then as 'live' iDteTactivc workshops. IndividuallgTOUP SUPPOrt Group support has been provided by a Sequence of four weekly workshops over a peri(NJ of a month. and repeated every three months. The first sequence has now been completed. and the next planned. Topics coping with worry. panic. poor sleep and 'getting back to norn]al.' Access to individual support has developed with increased prominence on the new website, although fewer I general are requiring additional support with the intr(Mluction of group sessions However, some health care providers who were aware of the REGAIN service ate utilizing the referra] option patients (including some late-idenlified VITT patients) into one-to-one sessions and a wider gmup of ¢liTJicians. Patient edueation New and more detailed support booklets have been developed to support the existing psychological onllne infonnation. These provide extended inforniation on managing worry, panic and sleep. In addition, a 'how to stop, smoking infommtion bklet has been developed as this appears to be a key concern for many vfE patients. Health care professlonal education A planned series of lectures, patient stories and health pmfessional experiences focusing on a range of topics around the topic of communication now being finalised in time for the new website. Six toplcs (including why bother to communicate, the basics of communication. and negotiating patient decision making) are being developed into an education package for health care professionals and expected to launch in 2025 with the intention fhat these will seek to secure CPD accreditation. INTERNAL The past year has been one of challenges. change and OppOrnitieS for Thronthosis UK. TiTne has been invested in securing the stwcture. including rr security and governance. Addition of new policie8 that safeguard. guide and fonnalise procedures. including the 'Abusive, Persistent or vexatious Complaints Policy. We have been extremely fortunate to secure pro bono support from nvo leading companies - Costello Medical. one of the mosl established independent agencies delivering medical cornmunications and health economic services, and Curious Health. an exceptional team of healthcare digital communications specialists. Work with both continues and 15 making a significant impact on the ouicome of projects that each has agreed to supporL It was also a year in which we said farewell to a long-serving member of staff, Annya Stephen5 Boal, who will be much missed by colleagues and the many patients and families who benefited from her knowledge, under51anding and care during her 17 years of service to Thrombosis UK.
THROMBOSIS UK Registered Charity No: 1090540 Company No: 4354472 TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025 FUNDIi4ISING Supporters took part in many events across the UK, kmd along with new we also welcomed repeat fundraisers and donors who so kindly continue to support Tlwombosis UK. Over the past year, fundraising efforts have secured over 80 unique events, which collectively raised a total of £89,227, averaging £l.115,34 per ndraISe[. This impressive achievement is a testament to the dedication and generosity of our suptK)rteTS. Among the many incredible fundraisers. Lewis Owen led the way by raising an impressive £14.000. He was followed by Lauren James, who raised over £6,IK)O. while Lyndsey Nichols contributed niore than £3,5(K). Andrew Woods and Jane Enticott each raised just over £3,(X)O. Their remarkable efforts have tnade a meaningful impact on the work of Thrombosis UK. Review has indicaied that marathons and runs are not only popular but have led to the raising of substantial funds, while wa]ks. challenges, Imd general events have also made significant contribulions. Although les8 'popular' evenls such as skydives. clin)bs. and swims do impact awareness raising. Continuing to diversify event opportunities nmintains broad appeal. however, planning is key with so many events in spring and summer. Thrombosis UK is immensely gratefi]I to all who fundraise and donate to the charity for our work lo Continue. Tragically, suptK)rt often comes after personal suffering or loss, and Thrombosis UK would like supporters and reiterate that iheir fundraising helps to make a significant difference to understanding, raising awareness of and supporting many individuals affected by venous thromboembolism. Due to their efforts. we can continue and be there for anyone at risk of, diagnosed with or who has lost a loved one due to vfE. to talk. share information and help them through the impact of thiombosis. FINANCIAL REVIEW During the year ended 31 January 2025 the charily made a deficit of £79.213 (2024: surplus of £255,442). Total incorning resources saw a decrease of 42Yo and expenditure increased by almost 48% in the y&gr. The material deCr&e in incoming resources was as a result of Thrombosis UK successfully receiving restricted grant monies in year ended 31 January 2024 (see Note 3 on page 19). The virtual events and aclivilies incurred a generally lower expenditure requirement. A significant proportion of the increase in expenditure during the year was attributable io the charity's strategic decision to appoint a temporary consultanf to fulfil the role of operations lead, alongside a higher number of travel fellowship grants awarded compared to the previous year. The economic and political uncertainty continues 10 affect the ability OF the charity to meaningfully forecast corporare and individual funding commitments and. as with last year, although the charity budgeted to meet its planned chItable activities through funds raised in the year it was prepared to have to utilise a proportion of its general unrestricted reserves if necessary. The net assets of the charity have been retained and have decreased from £667,220 in 2024 to £588,007 and this fits with the reserves policy of the charity. General unrestricted funds show a small deficit of £2,225 for the year. The Statement of Financial Activities is presented on page 15.
THROMBOSIS UK Registered Charity No: 1090540 Company No: 4354472 TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025 PLANS FOR FUTURE PERIODS The extended adopiion of virtual events, in particul educational webinars. conferences, and meetings. has continued to enable the charity's work to grow and extend across: Reach. Global collaborations. Ease of access for patients. the general public and healthcare professionals to access inforniation, support, and training. The online platfonn has not only proven to be more cost-effective, but also received extremely positive feedback from faculty, attendees, and sponsors. While the recording of sessions ensured a lasting legacy to access high quality education. The inaugural meeting for the newly fornied Thrombosis UK 'Professional Advisory Commiiiee, Ac), was held in 2024. Fornied with representatives from across the UK fron] health care and patient supporters, this coinmittee will.. To represent VTE stakeholders across the UK. Identify and inforni Thrombosis UK on relevant and key areas of VTE which should be included in the charity's strafrgy for delivering its 'Awareness, Research and Care, goals. Provide input and guidance on update or development of resources, conference agendas and advocacy activities across the UK NHS systenis. Be a first line referee for grant proposals or applications. Represent Thrombosis UK as an ambassador. In reviewing plans for 2024125, while Thrombosis UK is mind1 of the benefits of personal interaction the charity is keen io enable increased a¢¢ess and the virtual platforni and recording of webinars is currently enabling both greater access and a learning legacy. However. we are rnindful that continued monitoring is important and so the charity, along with review from the PAC, will Continue to carefully consider feedback, access and opportunity to ensure we are delivering in the most effective and efficient style suitable and welcomed by UK healthcare practitioners. REFERENCE AND ADMINISTRATION DETAILS A Board of ten Trnslees, who are also Directors of the company, govern Thrombosis UK. The Trnstees have the power to appoint and remove any member to act as Secretary 10 the charity and ajl - vote on the appoiniment of the Chairman, Treasurer, and other Honorary Officers. The charity seeks to ensure trustees are appointed io fulfil the changing and on- going needs of the charity's activities and outcomes. New trusfres are appointed with ihe unanimous approval of existing trustees. All Trnstees give freely of their time and expertise and receive no remuneration for their work as truseS. TILe current list of tstee$, who acted throughout the period of review. is given on page one. Trustees unaDiTnously a8reed to adopt a rotational model for the role of Medical Director of Thrombosis UK, with each appointee in post for two to three y&grs. In April 2016 Professor Simon Noble accepted an invitation to this role laking up the post in June 2016 until his retirement in 2025, with tbe objective of allowing for fresh ideas to percolate through the organisation. In November 2020 the Trustees agreed to extend retaining current directors for an extended 12 months while Governance work continued with the objective io write Trustee roles and job descriptions and develop a new Constitution. This work continues, and agreement was again in 2023 for this to be extended in order to implemeni a robust succession plan for Trustees so that skills, knowledge and experience are not lost, but instead, built on to secure the safe governance of Thrornbosis UK. Trustees. meetings are held a minimum of twice per year. Email correspondence is used to keep Trustees updated in between meetings and the CEO meets with Thrombosis UK'S Medi1 Ltads and lor Chair of Trustees between four- six times per Ye to discuss projects and agreed strategic and directional development.
THROMBOSIS UK Registered Charlty No: 1090540 Company No.: 4354472 TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUAR Y 2025 TRUSTEES, RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS The trustees (who are also directors of Thrombosis UK for the purposes of company law) dre responsible for preparing the Tni%tces' Report and the financial statemeJ]ts in dLLordance with applicable law and United Kingdom Accounting Standards (United KingdoTn Generally Accepted Accounting Ptaclice). Company law requires the lrnstees to picpare financial statements for each fJnaT]Cidl year, which give a true and fair view of the state of affairs of the chaTiLthle company and of the incoming resources and application of resollrce. includAng the incorne and eXnditure, of the charitahle company for ihe year. ID preparing these financial statements. the trnstees are required to: Select suitable accounting policies and then apply them consistently. Observe the Meth(5 and principles in ihe Charities Statement of Recomrnended Practice (SORP). Make judgements and estimates that are reasonable aT]d prudenL Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation. The trustees are responsible for keeping proper accounting records that disclose wilh reasonable accuTa¢y at any time the financial position of the charitable company and enable them to ensure that the financial statements Comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable compally and hence for taking reasonable steps for the prevention and detection of fraud and other iffegularities. In accordance wilh company law, the Trustees certify that.. 80 far as we &e aware, there is no relevant audit inforniation of which the company s auditors are unaware. and as Trnstees we have taken all the steps that we ought to have taJ(en in order to make ourselves aware of any relevant audit Inforntion and to establish that the company's auditors are aware of that Infornll0n. The trnstees are responsible for the maintenance and integrity of the COTrate and fmancial infonnation included on the charitable company's website. Legislation in Éhe United Kingdom governing the preparation and d5ssemination of fmancial statements may dilfer from legislation in other jurisdictions. At]DTfoRS The Auditors, Me%%rg Couch Bright KiT]g & Co., have expressed their willingness to conlinue in offjce and a resolution pmposing their re-appoiT]Iment will be put to the Trnstees at the forthcoming Annual GeT]eTal Meeling. SMALL COMPANY EXEMPTION This report has been prepared in accordance with the provisions applicable to companies entitled to the small Companies. exemption. STATEMENT AS TO DISCLOSURE OF tNFORMATION TO AUDITORS The Trustees who were in office on the date of approval of the financial statements have confirnied, as far as they are aware. that there is no relevanl audit infonnation of which the auditors are unaware. Each of the Trnsiees have confinned that they have taken all the steps that they ought to have taken as Trustees in order to make themselves aware of any relevxnl audit information and to establish that it has been communicated to the auditors. io
THROMBOSIS UK Registered Charity No: 1090540 Company No.: 4354472 TRUSTEES, ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2025 RESERVES POLICY In the course of the development of the charity we vjill take account of the need to have reserves, and a policy. to honour future funding committnents that we We will also ensure that funds are sufficient to cover one year's charitable aclivity plus sufficient fvnds to cover ail operating costs of the charity. RISK ASSESSMENT We consider the systems we have in place for the day-to-day operation of Thrombosis UK io be appropriate to our current size of operation, but we are aware that as we grow, we will need io develop and implement procedures and reporting regimes lo mitigate the risks associated with running a charitable company. PUBLIC BENEFIT The Trusiees ¢onfirni. to the best of their knowledge and belief, that they have complied with Section 4 of The Charities Act 2011 in respect of having due regard ro Public Benefit Guidance published by the Charity Commission, Approved by the Tn]stees on: September 2025 Janet Morgan Co.Chair
INDEPENDENT AUDITORS, REPORT TO THE MEMBERS OF THROMBOSIS UK Registered Charity No: 1090540 Opfinfion We have audiied the financial statements of Thrombosis UK for the year ended 31st January 2025 which comprise the primary statements such as the Statement of Financial Activities including Income and Expenditure Account, thc Balance Sheet, the Statement of Cash flows and the related notes. The financial reporting framework that has been applied in their prcparation is applicable law and United Kingdom Generally Accepted Accounting Practice including FRS 102 'The Financial Reporting SLindard xpplicable in the UK and Republic of Jreland (United Kingdom Generally Accepted Accounting PrdcÉiLL"). In our opinion the finanLial staiements: give a true and fair view of the state of the chdrilable conipany's affairs as at 31 st January 2025 and of its incoming resources and application of resources. including its income and expcndilure, for the year then ended; have been properly prepaTed in accordance with United Kingdom Gcnerally Accepted Accounting Practice applicable to smaller entities- have been prepared in accordance with the requirement5 Qf the Companies Aci 2(Ki6. Basis for opinion We conducted our audit in accordance with International Standards QD Auditing (UK) (ISAS (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our retKTrrt. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the fmancial statemenis in the UK, including the FRC'S Ethical Standard, and we have lfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficieni and appropriate to provide a basis for our opinion. Conclusions relating to going concern In auditing the financial statements, we have concluded that the trustees, use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have perfonned, we have not identified any material uncertainties relaiing to events or conditions thaL indlvidually or collectively, may cast significant doubt on the charitdble company's ability to continue ds a going concern for a tLYiod of at least twelve months from when the financial StatellntS are authorised foT ISSue. Our responsibilitics and the responsibilities of thc trusiees with respect to going concern are described in the relevant sections of this report. Other InfornOn The other infonnation comprises the infoTmation included in the trustees annual reporL other than the fmancial statements and our auditor's report theicon. The trustees are sponSible for the other information contained within the an1 report. Our opinion on Ihe financial statements does not cover the other infornlation and, except to the extcnt othenvise explicidy staled in our report, we do not express any forni of a88ur2nce conclusion ihereon. Our Tesponsibilily is to read the other infoThation and, in doing so. consider whether the otheT inforniation is materially inconsisteni with the fmancial staterDcniS or our knowledge obtained in the course of the audil or otherwise appears to be nteriallY misstated. If we identify such material inconsistencies or apparent maierial misstatements. we a required to detertnine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have perfornied. we conclude that there is a Material misslarement of this other information, we are required to report that fa¢t. We have nod]ing to report in this regard. 12
INDEPENDENf AUDITORS, REPORT TO THE MEMBERS OF THROMBOSIS UK Registered Charity No: 1090540 Opfinlons on other mattsrs prescribed by the Companies Act 2006 In our opinion. based on the work undenaken in the course of the audit: the infornlI0ll given in the trnstees, report (incorporating the directors, report) for the financial year for which the financial statements are prepared is consistent with the financial statements. and the truslees. report has been prepared in accordance with applicable legal requirements. Matters on which we are requlred to report by exception In the light of our knowledge dT]d understanding of the chariLqble company and its environment obtsined in the course of the audit. we have T]Ot idcntified material mis5tatcmenls in the trustees. report. We have nothing to report in respect of the following Tnatters in relation to which thc Companies Act 21)06 requires us to report to you il, in our opinion: adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us. or the financial statements are nor in agreernent with the accounting records and returns: or certain disclosures of trustees, remuneralion swified by law are not nmde. or we have not received all the infonnation and explanations we requi for our audit. or the trustees were not entitled to prepare the fmancial stateTnentg in accordance with the small companies, regime and take advantage of the small companies. exemptions in preparing ihe directors, report and frotn the requirement to prepare a strategic report. Responsibilitles of trustees As explained more fully in the Trustees, Responsibilities Statement set out on Pdge 10, the Trnstees (who are also the directors of ihe charitable Compdny for the purposes of the company law) rcsponsible for the prcparation of the fjnancial statements and for being satisfied that they give a lrne and fr view, and for such internal control as the trnstees detern)ine 18 necessary to enable the preparation of financial statements that aTe free from material misstatemenL whether due to fraud or tn preparing the fmancial statemeT]tS. the trustees re8pon%iblc for assessing the charitable company'4 dbi]iiy to continue as a going concern. disclosing, as applicable, Tnatter8 related to going concern and using the guing concern basis of accounting unless the truslees either intend to liquidate the charitable company or to cease operations, or have rcalistic alternative but to do so. Auditor's responsibilities for the audit of the financial statements Our objectives are to obtain reasonable assurance about whether the financial statements as a whole aTe free from malerial isslatement, whether due to fraud or eOr. and to issue an auditor's reporr thai includes our opinion. Reasonable assurance is a high level of assurance bul is nol a guarantee that an audit conducted in accordance with ISAS (UK) will always detect a materia] misstatement when it exists. Misstatemenis can lse from fraud or em)r and are considered material if. individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users tsken on the basis of these financial statements. 13
INDEPENDENT AIJDITORS, REPORT TO THE MEMBERS OF THROMBOSIS UK Registered Charity No: 1090540 Auditor's responsibilities for the audlt of the financial stalements {......Continued) Jrregularities. including fraud. are instances of non-compliance with laws and regulations. We design Procedures in line with our responsibilities. outlined above. to detect material misstatements in Tespect of Irregul1t1e8, including fraud. The specific procedures for this engagemllt and the extent to which thesc are capable of detecting irregularities, inLluding fraud is detailed below: We bave. Obtained an understanding OF the legal and regulatory fraCwOrk applicable to the entity and how the cntily is complying with that ftatnewurk. Obtained an ullderslanding of the entity's policies and pmcedures on compliance with laws and regulations. including docunlentation of any instances of non-cumpliance. Identified the laws and regulations that have significance in the conlcxt ol the entity., Obtained an understanding of the enlily's risk assessment process, including the risk of fraud. Assess¢d and evaluated the susceptibility of the entity's financial statements to llLat¢rial misstatement, through COr and Implemented procedures to enable the identification and testing of unusual or unexpected journal entries. Evaluated the assumptions and judgements used by management within significmt accounting estimates and assessed if these Indica evidence of management bias. Tested significant trallsactions, in particular the evaluation of the business rationale for any which appear unusual or outside th¢ company's nornial course of business. Reviewed the fmancial statements and tested the disclosures against supporting documentation,. Communicated relevant matters (including those above) io all members of the audit team to ensutt they underst(x)d the risks SPlfie to the entiry and the audit procedures planned to mitigaie these. Because of the inherent lin]itations of an audit, there is a risk that we will not delect all irregularities, including those leading to a material misststLrnent in the fmancial sratsments or non-compliance with regul&tion. This risk increases the more thai compliance with a law or regulaiion is removed from the events and transactions flected in the financial ststements, as we will be less likely lo become aware ot instsnces of non-compliance. Thc risk is s0 greater gardIng irregularilies occurring due to fraud rather than eIroT, as Iraud involves intentional Lonceaiment, forgery. collusion, omission or miSTcpresentation. A further description of our responsibilities for the dudit ol Ihe financi statetncnts is located on the Financial Reporting Council's website at: www.frc.org.uklaudiiorsresponsibilities. This dcscriplion fonns part of our auditOT'S reFKIrt. Use of our report This report is made solely to the ChItable company's rnembers, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's mernbers those lllatters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent pern)itted by law. we do not accept or assume responsibility to aT]yone other than the charitable company and its members as a body. foT our audit work, lor this report, or for the opinions we have fonned. Ms Tarwa Mo For and on behalf of Couch Bright King & Co Chartered Accountants & Statutory AuditOTS A FCA (Senior Statutory Auditor) 2 Tolherst Court Turkey Mill Business Park Ashford Road. Maidstone Kent ME14 5SF 99 September 2025 14
THROMBOSIS UK Registered Charity No: 10905401 Company No: 4354472 STATEMENT OF FINANCIAL ACTIVITIES (Including Jncome and Expenditure Account) FOR THE YEAR ENDED 31 JANUARY 2025 Year to 31.01.2025 Tolal Funds Year Unrestricted General Designated Restricted Funds Funds Funds 31.01.2024 Total Funds Notes Income: Donations. legacies and gifts 249.019 249,019 478.468 Incomefrom Charifable activities,. FAlucational meetings EveT]ts - Sponsorship 970 20,356 970 20,356 23,750 Incomefrom orher trading activities,. Online shop Awareness Literature Other Income 630 703 337 337 Investment Income Bank Interesi 22.544 22.544 3,367 Total income 293,226 293,226 506.918 Expenditure Costs of raising ndS 4,908 4.908 4,702 Costs of charitable activities 290,543 740 76.248 367,531 246.774 Total Expendlture 295,451 740 76,248 372.439 251.476 Net income and Net movements in funds (2,225) {740) (76,248) (79.213) 255,442 Transfers Net movements in funds (2,225) (740) {76,248) (79,213) 255,442 Reconciliation or rund$ Total funds At l FebrLWy 2024 382.307 740 284,173 667.220 411,778 Total Funds At 31 January 2025 14 380,082 207.925 588,(K)7 667.220 The statement of financial activili¢s includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities. 15
THROMBOSIS UK Registered Charlty No: 1090540 Con)pany No: 4354472 BALANCE SHEET AS AT 31 JANUARY 2025 Notes 2025 2024 Fixed Assets Tangible fixed assets io Current A&sets Debtors 12 17.312 22,027 Cash ai bank and in hand 586.045 667,574 603.357 689,6A)I Credilors (amounts falllng due within one yeAr) 13 15,350 22,381 Net Current Assets 588,007 667,220 Net Assets 588,007 667,220 Represented by: Restrlcted funds 14 207,925 284.173 Designated Funds 14 740 Unrestricted funds General funds 14 380.082 382.307 Total unr£stricted funds 588,007 667,220 Total funds 588,(K)7 667,220 The accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relaling to small companies. Approved by the Trustees on September 2025 Signed on ir behalf by Slmon Ha Trustee Janet Morgan Co-chair 16
THROMBOSIS UK Registsred Charity No: 1090540 Company No: 4354472 STA TEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 JANUARY 2025 Note 2025 2024 Cash flows from operating aetivitles: Net movements in fvnds for the year (79,213) 255,442 (79,213) 255,442 Movements in working capital DidendS and interest from investments (22,544) (3.367) Decrease/(Increase) in Debtors 4,715 5,912 (Decrease)Itncrease in Creditors (7,031) 3,269 Net cash generated by operating activities (104,073) 261.256 Cash flows from investing aetivities: Dividends and inleresi from invesunents 22,544 3.367 Cash used in investing activilies 22,544 3.367 Increase in cash and cash equivalents (81.529) 264,623 Cash and cash equivalents at beginning of the year 667,574 402,951 Cash and cash equivalents at the end of the year 586.045 667,574 17
THROMBOSIS UK Registered Charlty No: 1090540 Company No: 4354472 NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2025 i) Statutory Infurniation a) Company Stat$ The charity is a company limited by guarantee, incorporated in England and Wales. The registered offjce is 2 Tolherst Court. Turkey Mill Business Park, Ashford Road, Maidstone. Kent ME14 5SF. The principal office address is PO Box 1242, Chew Magna. Brislol, BS40 8WG. The members of the collipany are the trustees named on page l. In the event of the charity beiT]g wound p. the liability ill iespect of the gudrantee is limited to £1 per member of the charity. b) Charilable Status Thrombosis UK is a regAsteTed charity. registration number 1090540 dnd in consequence is exempt from tsxation on income aTisin¥ from and expended on its charitable activities. 2) Accounting Policies The PTincipal accounting policies, all of which have been applicd consistently throughout the year. are set oul below: Basis of Preparation The financial slatements have been prepared in accordance with Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to Charities prepaTing their accounts in accordance with the Financial Reporting Sfvdard applicable in the UK and Republic of trelaT]d issued in October 2019. the Financial Reporting Standd applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 201 l. the Companies Act 2006 and UK Generally Accepted Accounting Practice. Thrombosis UK meets the definition of a publi¢ benefit enlity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes. b) Functional and presentation currency The company's functional and presentation currency is GBP. Going Concern The Trustees continue to adopt the going coDcern basis in preparing the financial statements and confirm there are no material uncertaintses about the charity's ability to continue as a going concern. d) Flxed Assets and Depreclation Depreciation is charged on a straight-]ine basis. in order to write off the assets over their useful economic lives as follows- Computer and Other Equipment over 3 y&trs Assets acquired Under a Value of £1,5() are cbarged to the Statement of Financial Activities in the year of acquisition. Income and Expenditure recognition Income is recognised when the charity has entitleTnelll to the funds, any performancc condiLions attached io the items of income have been Tnet, it is probable that the iT]coTne will be received. and the amount can be m&2sured reliably. Incorne is deferred to match the period of the ternis of the grant docuMentilon or ternis of agreeent where applicable. The Charity. ID Common with many others of a similar size and organisation. derives a substantial pronIOn of its income from voluntary donations. Such donations are recognised and eniered into the accounting records when they are rcceived. Oiher income. such as bank interest. is accounled for on an accruals basis. On receipt, donated services are recognised on the basis of the value of the gift to the Charity which is the amouJ]t the Charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market. a corresponding amouni is then recognised in expenditure in the period of receipt. All expenditure is accounted for on accrnals basis. 18
THROMBOSIS UK Reglstered Charity No: 1090540 Company No: 4354472 NOTES TO THE ACCOUNTS FOR TItE YEAR ENDED 31 JANUARY 2025 Debtors and creditors receivable I payable within one year Debtors and creditors with no siaLed interest rate rcceivable or payable within one year recorded at traDsactiOT] price. Any losses arising from impairmeni are recognised in expenditure. g) Unrestricted Fund Unrestrictrd funds are donations, gifts and other incoming resources receivable or generated for the objects of the ChltY without further specified purpose and are available as geneIal ndS or for purposes as designated and agreed by all the Trustee5. h) Deslgnated Fund Designated funds (where applicable) a unrestricted funds earmarked by the Trustees for particular PUTposes. i) Restricted Fund Restricted fi]nds are donations, gifts and other incoming resources receivable or are generated for the objects of the charity with a specified PUry>se. They can only be used in accordance with the donor's wish or by the ternis of a public appeal. 21)25 202A 3) Donalions and gifts Restricled Research REGAIN Programme Education Grant Detect VTE Audit Study ISTH Grant 2022 1.000 753 16.0 255.020 28.673 UnrestTiCted Donations Gift Aid Donated Services 158.785 14,046 76.188 157.721 19.301 249,019 478.468 The number of general donations we have received during the year has seen a small increase compared to prior year. Thrombosis UK is irntnensely grateful io all of those who have organised a fundraising event for the charity. * Donated services coTt)prise pro bono support received from Costello Medical, who provided researcb data attalysis for the Detect VTE audit, and from Curious Health. who contributed comTnuni¢ation and PR services in support of our awareness campaign. 2025 2024 4) Income from charitable actfivitlos Educational Meetings Events - Sponsorship 970 20,356 23,750 21,326 23,750 5) Income from other tradlng activities Online shop- ebay sales Awareness Literature 703 630 337 337 1,333 19
THROMBOSIS UK Registered Charity No: 1090540 Company No: 4354472 NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2025 6) Costs of raising funds Donations Events 1,993 2,915 2,956 1.746 4,908 4.702 Analysls of eosts of charitable actlvltles R(*ricted Designated I Unrestricted 2025 2024 Research Grant Travel Fellowship Grants Awareness Resources Awareness Lilerature Thrombosis Education Dondted Scivices (Note 3) Website & App Costs Support Costs (Note 8) Governance Costs (Note 8) 54,207 54,207 12,IIK) 39,612 12,929 345 76,188 11.059 152,426 8.665 6,097 12.1(Ki 28,857 12,929 345 76.188 11.059 141.140 8.665 10,755 26.806 40.492 9,454 16,395 135,806 11,724 11,286 Total 76,248 291,283 367,531 246.774 8) Analysis of Support and Goven)ance costs Thrombosis UK initially idcn(ifies ils SilPPOrt costs which relate to the governance function and then the remalning support costs are apportioned as follows. General Governance Support Function Total 2025 Basis of apportlonment Trustee and other business rneeting8 274 274 Invoiced events Sa1]eS, wages and related cost5 121.888 121.888 Allocated on time General Office 13,401 13,401 Invoiced events Audit fees 6.930 6,930 Governance Consultancy Fees 13,104 13.104 Governance Legal and other professiona] fees 4.033 1,461 5.494 Governance 152.426 8,665 161,091 20
THROMBOSIS UK egistered Charity No: 1090540 Company No: 43S4472 NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JAIYUARY 2025 Analysis of Support 8nd Governance costs (......Contlnued) General Governance Support Function Total 202A Basis of apportionment Tn]slee and other business meetings 309 309 Invoiced events Salaries. wages and related costs 124,538 124,538 Allocated on time General Office 11.268 11.268 Invoiced eveDIs Audit fees 6,600 6,6(Y) Governance Consultancy Fees Governance l£gal and other professional fees 4,815 4.815 Governance 135,806 11.724 147.530 2025 2024 9) Staff Costs Salaries Employers National Insurance Pensions 110.682 5,374 5.832 113,260 5,395 5.883 121,888 124.538 The average number employed during the year was There are no employees with emoluments above £60,IKK). The Key Management Personnel of the chIlY comprise the TSteeS aDd the Chief Executive Officer. The Trustees have not received any remuneration for their work as Trustees. The total employee benefits of the Key Management Personnel were £49,720 (2024.. £48,931). io) Fixed Assets Com ui Total Cost At isr Febrnary 2024 Addilions 4.697 4,697 4.697 4.697 De redation At I" February 2024 Chae for year 4.697 4,697 4,697 4,697 Net Book Value 31 ¥ January 2025 Net Book Value 3151 January 2024 21
THROMBOSIS UK Regtstered Charity No: 1090540 Company No: 4354472 NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2025 2025 2024 ii) Cash and cash equivalents Cash at Bank 586,045 667,574 12) Debtors Gift Aid Prepayment5 & A¢¢rued Income 470 16,842 5,439 16.588 l7,312 22.027 13) Creditors: Amounts falling due Mqthin one year Other taxes Grants Payable Other creditor & Accruals Deferred Grants 2,360 2,900 10,089 3,172 7,900 11.309 15,350 22,381 14) Movement in Funds Atl" February 2024 Incoming Outgoing Resources Resources Transfers At 31st January 2025 Restricted funds: Research REGAIN Programrne VTE Grand Appeal ISTH Detect VTE Audit Study 6.459 12,960 3,143 14.069 247,542 6.459 12,960 3,143 3.314 195,009 10.755 52,533 Tot81 restricted funds 284.173 76,248 207,925 Unrostricted funds: Designated Funds REGAIN Programme 740 740 General Funds 382.307 293,226 295.45 I 380.082 Total unrestrlcted funds 383.047 293,226 296,191 380.082 se of Restricted Fullds Research- There was no donation received WardS the Thrombosis UK Research Fund in the year (2024: £1,000). REGAINProgramme-The REGAIN Programme, launched by the charity in 2021, aims to address the psychological impact of Venous Thromboembolism (VTE). including complicaiions associated with COVID-19. The initial development of the programme was nded by a restricied grant received in 2021, specifically allocated lo supp3rt research and patient support activities relating to VTE and Vaccine-Induced Itnmune Thrombotic Thrombocytopenia (VITT). During the year. no further restricted income was received in relation to the PTogramme (2024: £753). Total expenditure during the year amounted to £12,960, resulting in a closing restricted fund balance of £nil (2024: £12,960). 22
THROMBOSIS UK RegAstered Charity No: 1090540 Company No: 4354472 NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2025 of Restricted FuDds .ContiDued ISTH - In 2023124, Thrombosis UK received a restriLted grant of approximately £28.5(K) (equivalent to $37.500) from the International Society on ThroTnbosi8 and Haemostasis USTH) to support the developmeT]t of a Venous Thrombi)eTnbolism (vfE) Patient Inlonnation App, designed to impmvc patient access to essential inforniation about vfE. No additional income was received during thc year, and eXpendire totalled £10,755. The restricted nd caTried forward a closing balance of £3.314 at the year end. se of Unrestricted Funds General funds balance includes: (i) Designated Funds- REGAIN Programme Following the lallnch of the REGAIN clinical psychology research service programme in 2021, Ihe Trnstees established a designated fund in the year ended 31 January 2022 to support the ongoing development and delivery of this programme. No additional income was received for the programme during the year {2024.. £nil). This fund has been tully utilised in the year. (li) General - ThroTnbo¥is UK is conlmitted to raising awareness and advancing throvnbosis research in the UK. The Trnstees hdvc decided that as much as possible of the money donated by the general public will be used towards these objectives. Events - Sponsorship fees receivcd to enable the chariry to widen the Pllblic and Health Professionals. awareness of thron]bosis and thc relaled issues. Sponsorship fe&s of £20,356 were received in the year to support the National Thrombosis Week in May 2024 and the 'L£t's Ta]k Clots. Virtual Conference held as part of World Thrombosis Day celebrations in October 2024. Transfers between fvnds There were no transfers between funds in the year. 15) Capital Commitments There are no ourstanding comtnitments as at 31 January 2025. 16) Contingent Liabilities There are no contingent liabilities to report as at 31 January 2025. 17) Post Balance Sheet Events There are no adjusting OT non-adjusting events to report as at 31 January 2025. 18) Trtee Remuneration The Trustees have not received any remuneration for their work as Trustees. Expenses totalling £274 (2024: £309) have been reimbursed to two Trustees. 19) Related Party Transactions There were no Related Party Transactions in the year. 23
THROMBOSIS UK Registered Charity No: 1090540 Comppdny No: 43S4472 NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31 JANUARY 2025 20) Taxation Slaths The company being a registered charity {No.10905401 is not liable to Income and Corporation Taxes on its charitable activities. 21) Analysis of net assets between funds Unrestricted Funds D&signated Funds Restricted Funds Total 2025 Fixed assets Cash and current Tnvestments Other current assetsl(Liabilities) 378,120 1.962 207,925 586,045 1,962 Total 380.082 207,925 588,(X)7 Unrestrleted Funds Deslgnated Funds Restricted Funds Total 2024 Fixed assets Cash and current Investments Oiher current assetsl(Liabilities) 382,661 (354) 740 284,173 667.574 (354) Total 382.307 740 284,173 667,220 24